Venlo, the Netherlands, April 03, 2024 (GLOBE NEWSWIRE) -- QIAGEN N.V. (NYSE:QGEN, Frankfurt Prime Standard: QIA))) today announced a series of new products to further enhance cancer research as well as to enable urine collection and stabilization as a new approach for liquid biopsy. These three new products, along with the IVD version of QIAGEN's digital PCR platform QIAcuity set for launch in mid-2024, are to be featured at the annual meeting of the American Association for Cancer Research (AACR) in San D ...

Germantown, Maryland, and Venlo, the Netherlands, March 18, 2024 (GLOBE NEWSWIRE) -- QIAGEN (NYSE:QGEN, Frankfurt Prime Standard: QIA))) today announced a partnership with the International Panel Physicians Association (IPPA) to support and educate panel physicians around the globe on the latest tuberculosis (TB) screening requirements. A special focus will be on the new Interferon Gamma Release Assay (IGRA) requirements and the associated benefits for patients and healthcare providers. This collaboration f ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 or ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to or ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURI ...

It has been about a month since the last earnings report for Qiagen (QGEN) . Shares have added about 1.1% in that time frame, underperforming the S&P 500. Will the recent positive trend continue leading up to its next earnings release, or is Qiagen due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important catalysts. QIAGEN Q4 Earnings Lag, Operating Margin Expands QIA ...

QIAGEN N.V. (QGEN) recently launched QIAGEN Biomedical KB-AI, a new generative AI-driven knowledge base designed to propel drug discovery in the pharma and biotech industries. This new offering is designed for data scientists and bioinformaticians who are looking for the most comprehensive knowledge graphs to fuel data-driven drug discovery.The latest development will strongly boost the QIAGEN Digital Insights (“QDI”) bioinformatics business of the Genomics / NGS product group.News in DetailQIAGEN Biomedica ...

Venlo, the Netherlands, and Redwood City, California, Feb. 27, 2024 (GLOBE NEWSWIRE) -- QIAGEN (NYSE:QGEN, Frankfurt Prime Standard: QIA))) today announced the launch of QIAGEN Biomedical KB-AI, a new generative AI-driven knowledge base designed to propel drug discovery in the pharma and biotech industries. This new offering is designed for data scientists and bioinformaticians who are looking for the most comprehensive knowledge graphs to fuel data-driven drug discovery. QIAGEN Biomedical KB-AI is built on ...

QIAGEN N.V. (QGEN) recently announced two significant achievements in sustainability, recognized by My Green Lab — a non-profit organization dedicated to advancing sustainability in scientific research. The company earned the prestigious ACT (Accountability, Consistency, and Transparency) Environmental Impact Factor Label for the new QIAwave products and achieved My Green Lab Platinum certification for its Sample technologies R&D lab in Germany.These recognitions underscore QIAGEN’s commitment to sustainabi ...

Financial Data and Key Metrics Changes - Net sales for Q4 2023 were $503 million at constant exchange rates (CER), exceeding the outlook of at least $500 million [7] - Adjusted EPS for Q4 was $0.55 at CER, above the outlook of at least $0.53 CER [17] - For the full year, net sales were approximately $1.97 billion at CER, aligning with the sales outlook for 2023 [29] - Adjusted operating income margin rose to 28% in Q4, up from 27.1% in the same period of 2022 [37] - Adjusted EPS for the full year was $2.09 at CER, exceeding the outlook of at least $2.07 CER [29] Business Line Data and Key Metrics Changes - Non-COVID base business achieved 8% CER sales growth in Q4, driven by strong demand for consumables, which accounted for over 85% of total sales [7] - Sample Technologies saw 6% CER growth in non-COVID sales, with over 1,500 new automation systems placed in 2023 [8] - QuantiFERON TB test sales exceeded $400 million for the first time, achieving 24% CER growth [34] - QIAstat-Dx platform grew 7% CER in non-COVID sales for the full year, with over 1 million cartridges shipped [8] - Instrument sales declined 2% CER for non-COVID product groups in Q4, indicating a conservative spending environment [11] Market Data and Key Metrics Changes - The Americas region delivered mid-single-digit CER growth in Q4, with non-COVID product groups rising 9% CER [14] - Sales in China declined at a low single-digit CER rate for the full year, offset by higher sales in South Korea and India [15] - Europe, Middle East, and Africa region grew at a double-digit CER pace for both Q4 and the full year, excluding COVID-19 headwinds [36] Company Strategy and Development Direction - The company plans to invest in expanding its QIAGEN Digital Insight business and is looking at targeted bolt-on acquisitions [40] - A full-year 2024 outlook has been initiated, projecting at least $2 billion in sales at CER and adjusted EPS of at least $2.10 [9] - The company aims to improve adjusted operating income margin by at least 1 percentage point in 2024 from the 2023 level of 27% [23] Management's Comments on Operating Environment and Future Outlook - Management acknowledged the volatile macro environment but expressed confidence in the midterm growth perspective for QIAGEN [23] - The company expects a more subdued market demand in the first half of 2024, with a return to solid mid-single-digit CER growth in the second half [77] - Management highlighted the importance of maintaining a strong balance sheet and cash flow to support ongoing investments [40] Other Important Information - The adjusted gross margin declined to 65.7% in Q4 2023, down 1.3 percentage points from Q4 2022, due to adverse product mix changes [16] - Liquidity position was approximately $1.1 billion at the end of 2023, down from $1.4 billion at the end of 2022 [18] Q&A Session Summary Question: What are the expectations for OEM headwinds in 2024? - Management expects a headwind of around $15 million to $20 million in 2024, normalizing as the year progresses [51] Question: Can you elaborate on the Q1 guidance and OEM headwinds? - Management noted that the overall macro environment is challenging, particularly for capital expenditures, impacting OEM sales [59] Question: What is the outlook for the QIAcuity platform? - Management confirmed that QIAcuity is gaining market share due to its cost efficiency and faster results, with FDA and IVDR approvals expected in 2024 [90] Question: What are the dynamics affecting the China market? - Management indicated that the Life Science sector in China is still recovering, and they expect a gradual return to growth, emphasizing the importance of localization [64][110] Question: What is the company's M&A strategy moving forward? - The company maintains a focused M&A strategy, looking for opportunities that fit within its existing portfolio and reinforce growth pillars [112]

QIAGEN N.V.’s (QGEN) fourth-quarter 2023 adjusted earnings per share (EPS) were 55 cents (same at a constant exchange rate or CER), up 3.8% from the prior-year period. However, the figure missed the Zacks Consensus Estimate by 1.8%.The adjustment excludes the impact of certain non-recurring items like business integration, acquisition and restructuring-related expenses, purchased intangible amortization expenses and non-cash interest expense charges, among others.The GAAP EPS for the quarter was 42 cents, u ...

Qiagen (QGEN) reported $509.16 million in revenue for the quarter ended December 2023, representing a year-over-year increase of 2.3%. EPS of $0.55 for the same period compares to $0.55 a year ago.The reported revenue compares to the Zacks Consensus Estimate of $504.16 million, representing a surprise of +0.99%. The company delivered an EPS surprise of -1.79%, with the consensus EPS estimate being $0.56.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and h ...